Literature DB >> 8301266

Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival.

N T Neff1, D Prevette, L J Houenou, M E Lewis, M A Glicksman, Q W Yin, R W Oppenheim.   

Abstract

Treatment of chick embryos in ovo with IGF-I during the period of normal, developmentally regulated neuronal death (embryonic days 5-10) resulted in a dose-dependent rescue of a significant number of lumbar motoneurons from degeneration and death. IGF-II and two variants of IGF-I with reduced affinity for IGF binding proteins, des(1-3) IGF-I and long R3 IGF-I, also elicited enhanced survival of motoneurons equal to that seen in IGF-I-treated embryos. IGF-I did not enhance mitogenic activity in motoneuronal populations when applied to embryos during the period of normal neuronal proliferation (E2-5). Treatment of embryos with IGF-I also reduced two types of injury-induced neuronal death. Following either deafferentation or axotomy, treatment of embryos with IGF-I rescued approximately 75% and 50%, respectively, of the motoneurons that die in control embryos as a result of these procedures. Consistent with the survival-promoting activity on motoneurons in ovo, IGF-I, -II, and des(1-3) IGF-I elevated choline acetyltransferase activity in embryonic rat spinal cord cultures, with des(1-3) IGF-I demonstrating 2.5 times greater potency than did IGF-I. A single addition of IGF-I at culture initiation resulted in the maintenance of 80% of the initial ChAT activity for up to 5 days, during which time ChAT activity in untreated control cultures fell to 9%. In summary, these results demonstrate clear motoneuronal trophic activity for the IGFs. These findings, together with previous reports that IGFs are synthesized in muscle and may participate in motoneuron axonal regeneration and sprouting, indicate that these growth factors may have an important role in motoneuron development, maintenance, and recovery from injury.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8301266     DOI: 10.1002/neu.480241203

Source DB:  PubMed          Journal:  J Neurobiol        ISSN: 0022-3034


  43 in total

1.  Protective effect of a new hypothalamic peptide against cobra venom and trauma-induced neuronal injury.

Authors:  A A Galoyan; J S Sarkissian; T K Kipriyan; E J Sarkissian; E A Chavushyan; R M Sulkhanyan; I B Meliksetyan; S S Abrahamyan; Z A Avetisyan; N A Otieva
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

2.  IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of spinal muscular atrophy.

Authors:  Michela Murdocca; Arianna Malgieri; Andrea Luchetti; Luciano Saieva; Gabriella Dobrowolny; Elvira de Leonibus; Antonio Filareto; Maria Chiara Quitadamo; Giuseppe Novelli; Antonio Musarò; Federica Sangiuolo
Journal:  Mol Med       Date:  2012-09-25       Impact factor: 6.354

Review 3.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 4.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

Review 5.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

6.  The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice.

Authors:  Du-Chu Wu; Diane Bérangère Ré; Makiko Nagai; Harry Ischiropoulos; Serge Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-28       Impact factor: 11.205

Review 7.  Motor neuron disease: etiology, pathogenesis and treatment--a review.

Authors:  D J Donohoe; B Brady
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

8.  Motor neurone targeting of IGF-1 prevents specific force decline in ageing mouse muscle.

Authors:  Anthony M Payne; Zhenlin Zheng; María Laura Messi; Carol E Milligan; Estela González; Osvaldo Delbono
Journal:  J Physiol       Date:  2005-11-17       Impact factor: 5.182

Review 9.  Amyotrophic lateral sclerosis: current and future treatment strategies.

Authors:  B W Festoff
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 10.  Cell death in the nervous system: lessons from insulin and insulin-like growth factors.

Authors:  Isabel Varela-Nieto; Enrique J de la Rosa; Ana I Valenciano; Yolanda León
Journal:  Mol Neurobiol       Date:  2003-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.